View Now | C-Path in Europe: Moving Global Regulatory Science Forward
In support of C-Path’s mission to catalyze innovation that accelerates the path to a healthier world, we’re excited to invite you to this webinar to learn more about how C-Path’s new headquarters in Amsterdam will continue to improve public health, share expertise, data, risks and costs to move global regulatory science forward by facilitating public-private partnerships with members from the biopharmaceutical industry, government regulatory agencies, academic institutions, and patient groups in Europe.
Speakers include C-Path scientific leadership who will present on-going activities on key topics, including:
- Digital Technologies
- Real-World Evidence
- Model Informed Drug Development
- Complex Clinical Trials
Following presentations, audience questions will be answered by a panel of representatives from EFPIA, academia, EMA and patient groups.
| Topic | Speaker |
|---|---|
| Welcome and Introduction | Kristen Swingle Tomas Salmonson |
| C-Path global vision and mission | Klaus Romero |
| EMA Regulatory Science Strategy (RSS) & How C-Path Can Contribute | Cecile Ollivier |
| Drug Development Tools | Klaus Romero |
| Complex Clinical Trials and Digital Technologies | Terina Martinez Martijn Muller |
| Patient-Centric Drug Development and Real-world Evidence | Scottie Kern Jeff Barrett |
| Repurposed Drugs | Marco Schito |
| Collaborations and Training in Regulatory Science | Jeff Barrett Huong Huynh |
| Q&A for C-Path Speakers | C-Path Speakers |
| Panel Discussion (industry, academia, regulators, patient groups) | Lada Leyens Ralf Herold Dimitrios Athanasiou Franz Koenig |
| Closing remarks | Cecile Ollivier |
C-Path Speakers
- Kristen Swingle: Interim President & Chief Operating Officer (US)
- Tomas Salmonson: Member, Board of Directors (US) & Member, Board of Directors (Netherlands)
- Klaus Romero: Chief Science Officer & Executive Director of Clinical Pharmacology (US)
- Cecile Ollivier: EU Regulatory Science Advisor (US) & Member, Board of Directors (Netherlands)
- Terina Martinez: Executive Director Duchenne Regulatory Science Consortium & Critical Path to Therapeutics for the Ataxias (US)
- Martijn Muller: Senior Scientific Director, Critical Path for Parkinson’s Consortium (US)
- Scottie Kern: Executive Director, Electronic Clinical Outcome Assessment Consortium (US)
- Jeff Barrett: Senior Vice President; Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) Lead (US)
- Huong Huynh: Director, Regulatory Science (US)
Panelists
- Lada Leyens: Global Regulatory Lead, Clinical Trial Innovation & Digital Health at Roche
- Ralf Herold: Senior Scientific Officer, Taskforce Regulatory Science & Innovation at EMA
- Dimitrios Athanasiou: PDCO Member at EMA – EURORDIS Board, Member in World Duchenne Organization, European Patients Forum Greek Patient Association
- Franz Koenig: Associate Professor, Medical University of Vienna
To learn more about C-Path in Europe, visit https://c-path.org/c-path-in-europe/ and read C-Path European Nonprofit Established in Amsterdam.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.